{
    "name": "coagulation factor Xa recombinant, inactivated-zhzo",
    "comment": "Rx",
    "other_names": [
        "AndexXa",
        "andexanet alfa"
    ],
    "classes": [
        "Factor Xa Inhibitor Antidotes"
    ],
    "source": "https://reference.medscape.com/drug/andexxa-andexanet-alfa-coagulation-factor-xa-recombinant-inactivated-zhzo-999945",
    "pregnancy": {
        "common": [
            "Data are not available in pregnant women to inform patients of associated risks",
            "Safety during labor and delivery has not been evaluated",
            "Animal reproductive and development studies have not been conducted"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Data are not available regarding the presence in human milk, the effects on the breastfed child, or the effects on milk production",
            "The development and health benefits of breastfeeding should be considered along with the motherâ€™s clinical need for the drug and any potential adverse effects on the breastfed child or from the underlying maternal condition"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Serious and life-threatening adverse effects",
                    "description": [
                        "Monitor for thromboembolic events and initiate anticoagulation when medically appropriate",
                        "Monitor for symptoms and signs that precede cardiac arrest and provide treatment as needed",
                        "Treatment has been associated with the following serious and life-threatening adverse events, including",
                        "Arterial and venous thromboembolic events",
                        "Ischemic events, including myocardial infarction and ischemic stroke",
                        "Cardiac arrest",
                        "Sudden deaths"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [],
            "specific": [
                {
                    "type": "Thromboembolic and ischemic risks",
                    "description": [
                        "Monitor patients for signs and symptoms of arterial and venous thromboembolic events, ischemic events, and cardiac arrest",
                        "To reduce thromboembolic risk, resume anticoagulant therapy as soon as medically appropriate following therapy",
                        "Safety not evaluated in patients who experienced thromboembolic events or disseminated intravascular coagulation within two weeks prior to life-threatening bleeding event requiring treatment with this drug",
                        "Safety also not evaluated in patients who received prothrombin complex concentrates, recombinant factor VIIa, or whole blood products within seven days prior to the bleeding event"
                    ]
                },
                {
                    "type": "Reelevation or incomplete reversal of anti-FXa activity",
                    "description": [
                        "Compared wtih baseline, the ANNEXA-4 clinical trial observed a rapid and substantial decrease in anti-FXa activity corresponding to the IV bolus that was sustained through the end of the continuous infusion",
                        "Following the infusion, there was an increase in anti-FXa activity, which peaked 4 hr after infusion",
                        "After this peak, the antiFXa activity decreased at a rate similar to the clearance of the FXa inhibitors",
                        "~50% of patients experience >90% decrease from baseline anti-FXa activity after administration"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Note",
            "percent": "33"
        },
        {
            "name": "of patients were on antithrombotic therapy at time of event",
            "percent": "33"
        },
        {
            "name": "Deep vein thrombosis",
            "percent": "24"
        },
        {
            "name": "Ischemic stroke",
            "percent": "15"
        },
        {
            "name": "Acute myocardial infarction",
            "percent": "15"
        },
        {
            "name": "Pulmonary embolism",
            "percent": "25"
        },
        {
            "name": "deaths",
            "percent": "14"
        },
        {
            "name": "By bleeding type",
            "percent": "14"
        },
        {
            "name": "patient deaths  Intracranial bleeding",
            "percent": "10"
        },
        {
            "name": "GI bleeding",
            "percent": "19"
        },
        {
            "name": "Other bleeding types",
            "percent": "14"
        },
        {
            "name": "Intracranial bleeding",
            "percent": "10"
        },
        {
            "name": "GI bleeding",
            "percent": "19"
        },
        {
            "name": "Other bleeding types",
            "percent": "33"
        },
        {
            "name": "Note",
            "percent": "9"
        },
        {
            "name": "of patients were on antithrombotic therapy at time of event",
            "percent": "6"
        },
        {
            "name": "Cardiogenic shock",
            "percent": "6"
        },
        {
            "name": "Sudden death",
            "percent": "6"
        },
        {
            "name": "CHF",
            "percent": "3"
        },
        {
            "name": "Acute respiratory failure",
            "percent": "3"
        },
        {
            "name": "Cardiac arrest",
            "percent": "3"
        },
        {
            "name": "Cardiac thrombus",
            "percent": "3"
        },
        {
            "name": "Embolic stroke",
            "percent": "3"
        },
        {
            "name": "Iliac artery thrombosis",
            "percent": null
        },
        {
            "name": "Nonsustained ventricular tachycardia",
            "percent": null
        }
    ]
}